Sledge G W, Miller K D
Indiana University School of Medicine, Indianapolis, USA.
Semin Oncol. 1999 Feb;26(1 Suppl 2):6-10.
Treatment of metastatic breast cancer remains in flux. A flurry of new chemotherapeutic agents with activity against this disease has been identified in recent years, yet breast cancer remains a cause of significant morbidity and mortality. The taxanes in particular appear to hold promise for improved outcome and, in fact, are the treatment of choice for salvage therapy. Using the taxanes in high-dose regimens, with stem cell transplantation, in alternative schedules, and in combination regimens, including with biologic treatments, is the focus of future potential advances. Continued investigative energy and the discovery of novel drugs and therapeutic approaches for addition to established techniques hopefully will improve outcomes in the next generation of treatment strategies for metastatic breast cancer.
转移性乳腺癌的治疗仍在不断变化。近年来已发现一系列对该疾病有效的新型化疗药物,但乳腺癌仍是导致严重发病和死亡的原因。特别是紫杉烷类药物似乎有望改善治疗结果,事实上,它们是挽救治疗的首选药物。采用高剂量方案、联合干细胞移植、采用替代给药方案以及联合用药方案(包括与生物治疗联合)使用紫杉烷类药物,是未来潜在进展的重点。持续的研究精力以及发现除现有技术之外的新型药物和治疗方法,有望在下一代转移性乳腺癌治疗策略中改善治疗结果。